Roche Showcases Next-Generation Diagnostic Solutions and Latest Innovations

By LabMedica International staff writers
Posted on 21 Jul 2023

Image: navify digital solutions accelerate access to the wealth of innovation available to healthcare providers (Photo courtesy of Roche)

Roche Diagnostics (Basel, Switzerland) is showcasing a science-driven and patient-centric exhibit at AACC 2023. Attendees will have the opportunity to experience firsthand Roche's latest advancements in lab automation, core lab systems, and molecular and point-of-care solutions, as well as learn more about advancements in breakthrough high-medical-value diagnostic and digital solutions that are transforming patient care.

Roche is featuring its newest innovations including the cobas 5800, a compact, fully-automated molecular PCR-testing solution with a comprehensive menu of assays, and cobas pure integrated solutions, which combine clinical chemistry, immunoassay, and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs. The new cobas connection modules (CCM vertical), a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas connection modules, is also being highlighted, along with Roche’s vision for the transformation of mass spectrometry testing.

These systems can provide healthcare communities with the future benefit of an extended diagnostic platform offering clinical chemistry, molecular diagnostics, immunoassays, and mass spectrometry. The cobas pulse system, a next-generation point-of-care blood glucose management device, and digital platform, is also available for attendees to experience. Finally, Roche is introducing its navify digital solutions, an end-to-end integrated, secure and cohesive solution that delivers data-driven insights to enhance efficiency across the healthcare ecosystem.

Roche is also presenting seven Roche Idea Lab segments in booth 2201, where experts will be discussing topics such as mass spectrometry, digital solutions, point of care, and the use of high-medical-value assays when treating Alzheimer’s disease and heart failure. Scientific industry workshops include “The future of mass spectrometry from Roche,” “The future of diagnostics in the evolving Alzheimer’s disease care landscape” and “Precision medicine from a pathologist’s perspective in China.”

“We are excited to showcase our integrated solutions that simplify laboratory operations and provide clinicians with reliable and timely test results,” said Brad Moore, president and CEO of Roche Diagnostics North America. “Our collaboration with laboratory professionals is critical because they are supporting clinical decisions that can improve patient care, which is why we remain unwavering in our commitment to science, simplicity and partnership.”

Related Links:
Roche Diagnostics